(7α,17β)-3-oxo-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estr-4-en-17-yl acetate | 1334316-50-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (7α,17β)-3-oxo-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estr-4-en-17-yl acetate
• CAS: 1334316-50-5
• 化学式: C₃₄H₅₁F₅O₄S
• 分子量: 650.835
• InChiKey: RNZLIWNOJYWGEF-JZGNRXJWSA-N

物化性质

• 沸点：
  675.1±55.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9.13
• 重原子数：
  44.0
• 可旋转键数：
  15.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  60.44
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  (7α,17β)-3-oxo-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estr-4-en-17-yl acetate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 以83%的产率得到(7α,17β)-17-hydroxy-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estr-4-en-3-one
  参考文献：
  名称：

  Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

  摘要：

  Chemical starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer. Although prototypic steroidal downregulators such as 6a designed for intramuscular administration showed insufficient cellular potency, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]3-(trifluoromethyl)[1,2,4] triazolo[4,3-b] pyridazine (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.122
• 作为产物：
  描述：

  (7alpha,17beta)-17-(乙酰氧基)-7-[9-[(4,4,5,5,5-五氟戊基)硫代]壬基]雌甾-4-烯-3-酮 在 sodium periodate 作用下， 以 甲醇 、 水 为溶剂， 反应 2.5h， 以94%的产率得到(7α,17β)-3-oxo-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estr-4-en-17-yl acetate
  参考文献：
  名称：

  Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

  摘要：

  Chemical starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer. Although prototypic steroidal downregulators such as 6a designed for intramuscular administration showed insufficient cellular potency, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]3-(trifluoromethyl)[1,2,4] triazolo[4,3-b] pyridazine (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.122